Sign in

You're signed outSign in or to get full access.

Donald Slager

Director at MARTIN MARIETTA MATERIALSMARTIN MARIETTA MATERIALS
Board

About Donald W. Slager

Independent director of Martin Marietta Materials since 2016; age 63. Former President & CEO of Republic Services (2011–2021) and previously President & COO at Republic (2008–2011) and Allied Waste (2005–2008); EVP & COO at Allied Waste (2003–2004). He brings extensive operations, M&A integration, and logistics experience from 16+ years in C‑suite roles and 29+ years in general management; currently also serves on Eastman Chemical’s board .

Past Roles

OrganizationRoleTenureCommittees/Impact
Republic Services (NYSE: RSG)President & CEO2011–2021Led large-scale operations in solid waste industry; served as RSG director 2010–2021
Republic ServicesPresident & COO2008–2011Operational leadership prior to CEO role
Allied Waste IndustriesPresident & COO2005–2008Pre-merger operations leadership
Allied Waste IndustriesEVP & COO2003–2004Senior operating executive; earlier roles of increasing responsibility

External Roles

OrganizationRoleTenureCommittees
Eastman Chemical (NYSE: EMN)Independent DirectorCurrentAudit; Finance; Environmental, Safety & Sustainability
UTi Worldwide Inc. (former NYSE)Independent Director2009–Jan 2016Chair, Nominating & Corporate Governance; member, Compensation & Risk Committees
Phoenix Children’s HospitalDirectorCurrentBoard service (non-profit)

Board Governance

  • Independence: Classified as an independent, non-employee director; listed as independent in committee rosters, and Nominating & Corporate Governance Committee explicitly comprised of independent directors .
  • Committee assignments and chair roles:
    • Chair, Nominating & Corporate Governance Committee; members: Slager (Chair), Sue W. Cole, Thomas H. Pike; 2 meetings in 2024; 100% average attendance .
    • Member, Management Development & Compensation Committee (MD&C); 2025 MD&C report lists members Koraleski (Chair), Mack, Slager ; committee interlocks disclosure confirms members Koraleski, Mack, Slager, Wajsgras and no Item 404 relationships .
    • Member, Executive Committee (current members: Nye (Chair), Koraleski, Slager); Executive Committee held no meetings in 2024 .
  • Attendance and engagement:
    • Board met 4 times in 2024; all directors attended 100% of Board and assigned committee meetings; all directors attended the May 2024 Annual Meeting .
    • Independent directors met in executive session at each regularly scheduled Board meeting (4 executive sessions in 2024) .
  • Related-party oversight: Audit Committee processes and independence affirmed; reviews related party transactions; all Audit members are “financial experts” under SEC rules and independent under NYSE and company guidelines .

Fixed Compensation

ComponentAmountNotes
Fees Earned or Paid in Cash (2024)$138,750Reflects annual cash retainer plus committee chair/member roles (see schedule); deferred option available .
Stock Awards (2024)$170,435RSUs granted following 2024 Annual Meeting; 293 RSUs; grant date fair value per ASC 718 .
Change in Pension Value & Nonqualified Deferred Comp Earnings (2024)$4,786Interest on cash deferrals under Director plan .
All Other Compensation (2024)$13,379Dividend equivalents paid on common stock units (no perquisites) .
Total (2024)$327,350Sum of components .

Cash retainer schedule applicable to non-employee directors (paid quarterly, FY2024):

  • Annual Board retainer: $125,000; Nominating & Corporate Governance Committee chair retainer: $15,000; Audit Committee chair retainer: $20,000; MD&C Committee chair retainer: $20,000; Finance Committee chair retainer: $15,000; Ethics, Environment, Safety & Health Committee chair retainer: $15,000; Audit Committee member retainer: $5,000; Lead Independent Director retainer: $35,000; directors reimbursed for travel; no personal aircraft use or perquisites in 2024 .

Deferred Compensation Program for Directors:

  • Directors may elect to receive fees in common stock units or cash; stock units credited at 100% of FMV; minimum 3-year deferral; cash deferrals credited with interest at prime; dividend equivalents paid; units have no voting or investment power .

Performance Compensation

  • Director equity is not performance-conditioned. Non-employee directors received 293 RSUs in May 2024, fully vested at grant; directors must defer at least 50% of RSUs until retirement; remaining RSUs may be settled in shares shortly after grant; no options outstanding for directors as of 12/31/2024 .
Equity Grant Detail (Director RSUs)Grant DateUnitsFair ValueVestingDistribution
Annual RSU awardMay 2024293$170,435Fully vested at grantDeferred until retirement (≥50% mandatory deferral)

Company-wide compensation governance features (context for board oversight of MD&C):

  • Robust stock ownership guidelines (5x annual retainer for directors); anti-hedging and anti-pledging policies; clawback policy implementing SEC/NYSE rules; annual say-on-pay approval in 2024 was 95% .

Other Directorships & Interlocks

CompanyRoleCommittee RolesInterlock/Conflict Notes
Eastman Chemical (EMN)Independent DirectorAudit; Finance; Environmental, Safety & SustainabilityNot an MLM customer/supplier disclosed; no Item 404 relationships at MLM’s MD&C .
UTi WorldwideIndependent DirectorChair Nominating & Corporate Governance; member Compensation & RiskUTi is defunct; historic role; no current MLM interlock .
Republic ServicesDirectorBoard member 2010–2021No MLM interlock disclosed .
Phoenix Children’s HospitalDirectorBoard serviceNon-profit .

MD&C Committee interlocks and insider participation: None of MD&C members (Koraleski, Mack, Slager, Wajsgras) have relationships requiring Item 404 disclosure; no executive officer–director interlocks with other companies’ compensation committees .

Expertise & Qualifications

  • More than 16 years of C‑suite experience; 29+ years of general management in complex, capital-intensive, logistics businesses; extensive M&A, integration, and strategic development expertise; multi-board experience across two publicly traded companies .

Equity Ownership

HolderBeneficial Ownership (Shares)Units/RSUs Detail% OutstandingPledged?
Donald W. Slager4,443Common stock units credited under director plan as of 3/7/2025: 0; RSUs held as of 12/31/2024: 4,443; no options outstandingNone of individual directors >1%None pledged .

Stock ownership policy and restrictions:

  • Directors must hold stock equal to 5x annual cash retainer; all directors are in compliance. Hedging and pledging are prohibited; no margin purchases or pledging allowed .

Insider Trades (Form 4)

Filing DateTransaction DateTypeSecurities TransactedPricePost-Transaction OwnershipSource
2025-05-162025-05-15Award (RSU/Common Stock)308$552.864,751https://www.sec.gov/Archives/edgar/data/916076/000112760225014647/0001127602-25-014647-index.htm
2024-05-172024-05-16Award (RSU/Common Stock)293$581.694,443https://www.sec.gov/Archives/edgar/data/916076/000112760224015865/0001127602-24-015865-index.htm

Governance Assessment

  • Strengths: Independent director with deep operating and M&A experience; Chairs Nominating & Corporate Governance, directly influencing board composition and governance policies; 100% attendance; active executive sessions; robust ownership and anti-hedging/pledging policies; say-on-pay support at 95% indicates strong investor alignment .
  • Alignment: Receives a balanced mix of cash and fully vested RSUs with mandatory deferral until retirement; holds RSUs/stock units with no voting rights prior distribution, avoiding control concerns; no perquisites; no shares pledged .
  • Conflicts/Interlocks: MD&C membership disclosed with no Item 404 transactions; no disclosed related-party transactions; external roles (Eastman Chemical) do not indicate direct conflicts with MLM; Audit Committee monitors related-party transactions .
  • Process Quality: Board and committee charters reviewed annually; formal evaluations at board/committee/individual level; clear tenure guidelines; independent director majority; executive sessions at each regular meeting .
  • Red Flags: None disclosed regarding attendance, related-party transactions, hedging/pledging, or compensation anomalies. Note: Director equity is fully vested at grant (time-based, not performance-based), which is common for directors but offers less performance contingency than PSUs; mitigated by mandatory deferral and ownership guidelines .

Overall implication: Slager’s governance footprint—chairing Nominating & Corporate Governance, serving on MD&C and Executive—combined with flawless attendance and strong compliance posture, supports investor confidence; absence of related-party exposures and anti-hedging/pledging discipline further reduces governance risk .